Jonas Hue

Dr. Jonas Hue

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2023 in Lab on a Chip
Verified
Journal Article
Open access
PDF file
FCFrancois Chesnais
Francois Chesnais
JJJordan Joel
Jordan Joel
JHJonas Hue
Jonas Hue
SSSima Shakib
Sima Shakib
LSLucy Di Silvio
Lucy Di Silvio
LVLorenzo Veschini
Lorenzo Veschini
We present a new continuously perfusable, customisable, and matrix free vasculature on chip (VoC) platform enabling to study microvascular functions and responses to perturbations under physiologic perfusive flow.

15 January 2022 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
FCFrancois Chesnais
Francois Chesnais
JHJonas Hue
Jonas Hue
ERErrin Roy
Errin Roy
MBMarco Branco
Marco Branco
RSRuby Stokes
Ruby Stokes
LVLorenzo Veschini
Lorenzo Veschini
Endothelial cells (ECs) are heterogeneous across and within tissues, reflecting distinct, specialised functions. EC heterogeneity has been proposed to underpin EC plasticity independently from vessel microenvironments. However, heterogeneity driven by contact-dependent or short-range cell–cell crosstalk cannot be evaluated with single cell transcriptomic approaches, as spatial and contextual information is lost. Nonetheless, quantification of EC heterogeneity and understanding of its molecular drivers is key to developing novel therapeutics for cancer, cardiovascular diseases and for revascularisation in regenerative medicine. Here, we developed an EC profiling tool (ECPT) to examine individual cells within intact monolayers. We used ECPT to characterise different phenotypes in arterial, venous and microvascular EC populations. In line with other studies, we measured heterogeneity in terms of cell cycle, proliferation, and junction organisation. ECPT uncovered a previously under-appreciated single-cell heterogeneity in NOTCH activation. We correlated cell proliferation with different NOTCH activation states at the single-cell and population levels. The positional and relational information extracted with our novel approach is key to elucidating the molecular mechanisms underpinning EC heterogeneity.

23 April 2023 in Oral Oncology
Verified
Journal Article
Open access
JHJonas Hue
Jonas Hue
ZVZaneta Valinciute
Zaneta Valinciute
STSelvam Thavaraj
Selvam Thavaraj
LVLorenzo Veschini
Lorenzo Veschini
Routine haematoxylin and eosin (H&E) photomicrographs from human papillomavirus-associated oropharyngeal squamous cell carcinomas (HPV + OpSCC) contain a wealth of prognostic information. In this study, we developed a high content image analysis (HCIA) workflow to quantify features of H&E images from HPV + OpSCC patients to identify prognostic features and predict patient outcomes. First, we have developed an open-source HCIA tool for single-cell segmentation and classification of H&E images. Subsequently, we have used our HCIA tool to analyse a set of 889 images from diagnostic H&E slides in a retrospective cohort of HPV + OpSCC patients with favourable (FO, n = 60) or unfavourable (UO, n = 30) outcomes. We have identified and measured 31 prognostic features which were quantified in each sample and used to train a neural network (NN) model to predict patient outcomes. Univariate and multivariate statistical analyses revealed significant differences between FO and UO patients in 31 and 17 variables, respectively (P < 0.05). At the single-image level, the NN model had an overall accuracy of 72.5% and 71.2% in recognising FO and UO patients when applied to test or validation sets, respectively. When considering 10 images per patient, the accuracy of the NN model increased to 86.7% in the test set. Our open-source H&E analysis workflow and predictive models confirm previously reported prognostic features and identifies novel factors which predict HPV + OpSCC outcomes with promising accuracy. Our work supports the use of machine learning in digital pathology to exploit clinically relevant features in routine diagnostic pathology without additional biomarkers.

7 January 2024 in medRxiv
Verified
Preprint
Open access
PDF file
JHJonas Hue
Jonas Hue
JEJinendra Ekanayake
Jinendra Ekanayake
JDJamshid Dehmeshki
Jamshid Dehmeshki
JDJagtar Dhanda
Jagtar Dhanda
Background: Management of skin cancers are heavily dependent on clinical diagnosis via dermoscopy. Dermoscopic morphology of basal cell carcinomas (BCC) and melanomas influence diagnosis and may be influenced by anatomic location. Objective: In this study, we aimed to investigate the morphologic differences between anatomic sites of the head and neck (H&N) versus other body sites in basal cell carcinomas and melanomas. Patients and methods: The publicly available HAM10000 dataset was used in this study. Morphometric image analysis of the BCCs (n=422) and melanomas (n=868) in this dataset was performed using an open-source image analysis software. Univariate and multivariate statistical analysis was done to identify differences between H&N and other anatomic sites. The multifactorial data was further interrogated with dimensionality reduction techniques, linear discriminant analysis, principal component analysis and t-distributed stochastic neighbour embedding. Results: Univariate and multivariate statistical analyses revealed significant differences between H&N and other sites for both BCCs and melanomas ( P <0.05). Fifty-three univariate and 11 multivariate features were found to be statistically significant in the BCC group. Thirteen univariate and 8 multivariate features were statistically significant in the melanoma group. Dimensionality reduction via linear discriminant analysis of the BCC groups revealed modest separation of the data by anatomical site. However, melanomas appeared to be more homogenous across H&N and other body sites. Conclusion: BCCs of the H&N may be morphologically different to BCCs of other body sites. This may influence the accuracy of computer-assisted diagnostic tools and specialist clinicians working predominantly in the H&N region should exercise caution when employing these tools in clinical practice.

27 March 2024 in EJC Skin Cancer
Verified
Journal Article
Open access
JHJonas Hue
Jonas Hue
JEJinendra Ekanayake
Jinendra Ekanayake
JDJamshid Dehmeshki
Jamshid Dehmeshki
JDJagtar Dhanda
Jagtar Dhanda

4 June 2025 in Organoids
Verified
Journal Article
Open access
PDF file
EFElisabetta Ferrero
Elisabetta Ferrero
JHJonas Hue
Jonas Hue
MFMarina Ferrarini
Marina Ferrarini
LVLorenzo Veschini
Lorenzo Veschini
Tumour-associated angiogenesis plays a key role at all stages of cancer development and progression by providing a nutrient supply, promoting the creation of protective niches for therapy-resistant cancer stem cells, and supporting the metastatic cascade. Therapeutic strategies aimed at vascular targeting, including vessel disruption and/or normalisation, have yielded promising but inconsistent results, pointing to the need to set up reliable models dissecting the steps of the angiogenic process, as well as the ways to interfere with them, to improve patients’ outcomes while limiting side effects. Murine models have successfully contributed to both translational and pre-clinical cancer research, but they are time-consuming, expensive, and cannot recapitulate the genetic heterogeneity of cancer inside its native microenvironment. Non-animal technologies (NATs) are rapidly emerging as invaluable human-centric tools to reproduce the complex and dynamic tumour ecosystem, particularly the tumour-associated vasculature. In the present review, we summarise the currently available NATs able to mimic the vascular structure and functions with progressively increasing complexity, starting from two-dimensional static cultures to the more sophisticated tri-dimensional dynamic ones, patient-derived cultures, the perfused engineered microvasculature, and in silico models. We emphasise the added value of a “one health” approach to cancer research, including studies on spontaneously occurring tumours in companion animals devoid of the ethical concerns associated with traditional animal studies. The limitations of the present tools regarding broader use in pre-clinical oncology, and their translational potential in terms of new target identification, drug development, and personalised therapy, are also discussed.